Clinical Trial Update: A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies [Phase 4]

View source ↗

Summary

Phase 4 study of once-weekly epoetin beta (Recormon) in anemic participants with solid and lymphoid malignancies assessed quality of life and treatment response…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia

Drugs mentioned

• Epoetin Beta (Recormon) (epoetin beta)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Anemia | Phase 4 | Status: COMPLETED